Literature DB >> 9155834

Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma.

A T Kotsimbos1, M Humbert, E Minshall, S Durham, R Pfister, G Menz, J Tavernier, A B Kay, Q Hamid.   

Abstract

BACKGROUND: Intrinsic asthma is characterized by an increased number of activated eosinophils and macrophages and an increased expression of the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) in the bronchial mucosa.
OBJECTIVE: This study was carried out to investigate the expression of alpha GM-CSF receptor (alpha GM-CSFr) messenger RNA and protein in the bronchial mucosa of patients with intrinsic or atopic asthma and of control subjects and to correlate the expression of alpha GM-CSFr to the number of EG2+ cells (eosinophils) and CD68+ cells (macrophages) and pulmonary function.
METHODS: Nineteen patients with stable asthma (9 with atopic and 10 with intrinsic asthma) and 22 normal control subjects (12 atopic and 10 nonatopic subjects) were recruited, and FEV1 (percent predicted) and PC20 were measured before bronchoscopy. Endobronchial biopsy specimens were obtained and examined for membrane-bound alpha GM-CSFr by using in situ hybridization and immunocytochemistry.
RESULTS: alpha GM-CSFr mRNA- and protein-positive cells were identified in biopsy specimens from all four groups studied. There was no significant difference in the number of cells expressing alpha GM-CSFr mRNA and protein in patients with atopic asthma compared with atopic and nonatopic control subjects. However, the numbers of alpha GM-CSFr mRNA- and protein-positive cells were significantly higher in nonatopic patients with asthma compared with atopic patients with asthma and atopic and nonatopic control subjects (p < 0.001). In the patients with intrinsic asthma, the number of alpha GM-CSFr mRNA-positive cells per millimeter of basement membrane correlated with numbers of CD68+ cells (r2 = 0.87, p < 0.001) but not with EG2+ cells, and colocalization studies demonstrated that 80% of the cells expressing alpha GMCSFr mRNA were CD68+. The expression of GM-CSF was also significantly increased in patients with intrinsic asthma compared with those with atopic asthma and control subjects (p < 0.05). In addition, in intrinsic asthma, there was a correlation between alpha GM-CSFr mRNA and FEV1 (r2 = 0.61, p < 0.05).
CONCLUSION: These results demonstrate that elevated numbers of cells expressing alpha GM-CSFr can be detected in nonatopic asthma but not in atopic asthma and suggest that this increased expression is predominantly macrophage-associated and may play an important pathophysiologic role in intrinsic asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155834     DOI: 10.1016/s0091-6749(97)70029-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

3.  Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD.

Authors:  S Saha; C Doe; V Mistry; S Siddiqui; D Parker; M Sleeman; E S Cohen; C E Brightling
Journal:  Thorax       Date:  2009-02-12       Impact factor: 9.139

4.  Airway epithelium in atopic and nonatopic asthma: similarities and differences.

Authors:  Prathap Pillai; Chris J Corrigan; Sun Ying
Journal:  ISRN Allergy       Date:  2011-12-29

5.  MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation.

Authors:  Magdalena M Gorska; Qiaoling Liang; Susan J Stafford; Nicolas Goplen; Nilesh Dharajiya; Lei Guo; Sanjiv Sur; Matthias Gaestel; Rafeul Alam
Journal:  J Exp Med       Date:  2007-06-25       Impact factor: 14.307

6.  Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.

Authors:  Nestor A Molfino; Piotr Kuna; Jonathan A Leff; Chad K Oh; Dave Singh; Marlene Chernow; Brian Sutton; Geoffrey Yarranton
Journal:  BMJ Open       Date:  2016-01-06       Impact factor: 2.692

Review 7.  Aluminum Adjuvant-Containing Vaccines in the Context of the Hygiene Hypothesis: A Risk Factor for Eosinophilia and Allergy in a Genetically Susceptible Subpopulation?

Authors:  Todd D Terhune; Richard C Deth
Journal:  Int J Environ Res Public Health       Date:  2018-05-03       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.